Research programme: phosphodiesterase inhbitors - Intra-Cellular Therapies

Drug Profile

Research programme: phosphodiesterase inhbitors - Intra-Cellular Therapies

Alternative Names: ITI 002 series; PDE1 inhbitors - Intra-Cellular Therapies; PDE2 inhibitors - Intra-Cellular Therapies; PDE9 inhibitors - Intra-Cellular Therapies

Latest Information Update: 05 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors; Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 2 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Neurodegenerative disorders
  • Research Alzheimer's disease; Schizophrenia

Most Recent Events

  • 03 Nov 2014 Intra-Cellular Therapies and Takeda terminate their collaboration on phopshodiesterase 1 inhibitors for CNS disorders
  • 01 Mar 2014 Early research in Alzheimer's disease in USA (Oral)
  • 01 Mar 2014 Early research in Schizophrenia in USA (Oral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top